.Charles Baum, M.D., Ph.D., that managed Mirati Rehabs' $ 5.8 billion purchase to Bristol Myers Squibb in 2015, is taking the command of younger biotech Terremoto Biosciences.Baum's "substantial experience in medicine advancement, and proven track record in advancing high-impact medicines, will be instrumental," outbound CEO Peter Thompson, M.D., stated in a July 25 release. Thompson will certainly retain his chair as board chairperson..Baum, a competent physician-scientist, was actually the owner, head of state and also CEO of oncology-focused Mirati. Prior to that, he assisted build cancer cells medicines at Pfizer as well as Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Now, Baum will definitely function as chief executive officer at Terremoto, a provider creating little molecules to target disease-causing proteins-- like those located in cancerous tumor tissues-- utilizing covalent connections. Existing therapies that use covalent bonds largely target the amino acid cysteine. Nevertheless, of the 20 amino acids that comprise proteins, cysteine is actually the least popular. Terremoto is actually rather targeting one of the vital amino acids, amino acid lysine, which is discovered in nearly all healthy proteins.Through targeting amino acid lysine and various other amino acids, Terremoto wants to manage earlier undruggable ailments and also produce first-in-class medicines..The biotech, located in South San Francisco, raised $75 thousand in series A backing in 2022. A little greater than a year later, the biotech much more than doubled that amount in a $175 million series B.